Skip to main content
logo
Eloxx Pharmaceuticals, Inc. (ELOX)
NASDAQ: ELOX · Real-Time Price · USD
13.15
-0.05 (-0.38%)
Oct 30, 2026, 10:42 AM EDT - Market open

Eloxx Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--6.36---
Revenue Growth
------
Gross Profit
--6.36---
Selling, General & Admin
5.733.385.258.6911.3920.55
Research & Development
6.153.063.588.623.0321.8
Operating Expenses
11.886.448.8317.2934.4242.35
Operating Income
-11.88-6.44-2.47-17.29-34.42-42.35
Interest Expense
-0.29-1.05-1.14-1.15-1.95-1.26
Interest & Investment Income
0.090.030.030.250.270.01
Currency Exchange Gain (Loss)
-----00
Other Non Operating Income (Expenses)
-0.010.070.431.280.03-
EBT Excluding Unusual Items
-12.1-7.39-3.16-16.91-36.07-43.6
Merger & Restructuring Charges
------1
Gain (Loss) on Sale of Assets
000.040.29--
Other Unusual Items
1.451.39-0.03-0.44-0.54
Pretax Income
-10.65-6-3.14-17.05-36.07-66.73
Net Income
-10.65-6-3.14-17.05-36.07-66.73
Net Income to Common
-10.65-6-3.14-17.05-36.07-66.73
Net Income Growth
------
Shares Outstanding (Basic)
410000
Shares Outstanding (Diluted)
410000
Shares Change
-228.50%46.22%18.66%23.86%74.36%
EPS (Basic)
-2.84-5.34-9.20-72.98-183.13-419.65
EPS (Diluted)
-2.84-5.34-9.20-72.98-183.15-419.65
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-16.02-6.33-4.72-14.34-31.91-35.09
Free Cash Flow Per Share
-4.28-5.64-13.80-61.37-162.04-220.68
Gross Margin
--100.00%---
Operating Margin
---38.81%---
Profit Margin
---49.43%---
Free Cash Flow Margin
---74.15%---
EBITDA
--6.4-2.43-17.18-34.34-42.23
EBITDA Margin
---38.26%---
D&A For EBITDA
-0.040.040.110.080.11
EBIT
-11.88-6.44-2.47-17.29-34.42-42.35
EBIT Margin
---38.81%---